AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. GNPX
  4. [DEF 14A] Genprex, Inc. Definitive Proxy Statement

[DEF 14A] Genprex, Inc. Definitive Proxy Statement

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
DEF 14A

Filing content is currently unavailable.

Source:

Stock GNPX logo
Genprex Inc

NASDAQ:GNPX

GNPX Rankings

#6145 Ranked by Market Cap
N/A Ranked by Dividends
#56 Top Loser

GNPX Latest News

Aug 18, 2025
Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers
Aug 4, 2025
Genprex Issues Stockholder Letter and Provides 2025 Corporate Update
Jun 24, 2025
Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Jun 23, 2025
Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions
Jun 3, 2025
Genprex to Participate at BIO 2025 International Convention

GNPX Latest SEC Filings

Aug 18, 2025
[8-K] Genprex, Inc. Reports Material Event
Aug 15, 2025
[8-K] Genprex, Inc. Reports Material Event
Aug 5, 2025
[RW] Genprex, Inc. SEC Filing
Aug 4, 2025
[8-K] Genprex, Inc. Reports Material Event
Jul 3, 2025
[PRE 14A] Genprex, Inc. Preliminary Proxy Statement

GNPX Stock Data

7.54M
33.36M
0.33%
1.41%
2.49%
Biotechnology
Pharmaceutical Preparations
United States
AUSTIN